Drugs / HWH340
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03415659 | Mar 2018 → Mar 2021 | cancer, hereditary neoplastic syndrome | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HWH340 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03415659 ↗ |
| Route | Oral | “HWH340 tablet, oral administration” NCT03415659 ↗ |